Daniela R Crousillat1, Nasrien E Ibrahim2,3. 1. Massachusetts General Hospital, 55 Fruit Street GRB-800, Boston, MA, 02114, USA. 2. Massachusetts General Hospital, 55 Fruit Street GRB-800, Boston, MA, 02114, USA. neibrahim@mgh.harvard.edu. 3. Harvard Medical School, Boston, MA, USA. neibrahim@mgh.harvard.edu.
Abstract
PURPOSE OF REVIEW: Heart failure (HF) is prevalent among women and remains a leading cause of morbidity and mortality in the United States. Currently, 3 million women live with HF and the prevalence is projected to continue to increase. The purpose of this review is to highlight sex differences in the use and response to evidence-based pharmacological, device, and advanced HF therapies, as well as explore emerging areas of research in sex differences in the treatment of HF. RECENT FINDINGS: Under-representation of women in clinical HF trials has limited our understanding of sex-related differences in the treatment and outcomes of HF. Important sex differences exist in the use of evidence-based HF therapies and clinical response among women with HF. In general, women tend to obtain the same clinical benefit from evidence-based HF drug and device therapies, but the utilization rates of guideline-directed medical therapies remain poor compared to men. Future research efforts should focus on increasing the enrollment of women in HF trials to help gain helpful insight into sex-specific differences in treatment effects and subsequent clinical outcomes.
PURPOSE OF REVIEW: Heart failure (HF) is prevalent among women and remains a leading cause of morbidity and mortality in the United States. Currently, 3 million women live with HF and the prevalence is projected to continue to increase. The purpose of this review is to highlight sex differences in the use and response to evidence-based pharmacological, device, and advanced HF therapies, as well as explore emerging areas of research in sex differences in the treatment of HF. RECENT FINDINGS: Under-representation of women in clinical HF trials has limited our understanding of sex-related differences in the treatment and outcomes of HF. Important sex differences exist in the use of evidence-based HF therapies and clinical response among women with HF. In general, women tend to obtain the same clinical benefit from evidence-based HF drug and device therapies, but the utilization rates of guideline-directed medical therapies remain poor compared to men. Future research efforts should focus on increasing the enrollment of women in HF trials to help gain helpful insight into sex-specific differences in treatment effects and subsequent clinical outcomes.
Entities:
Keywords:
Disparities; Gender; Heart failure; Sex; Women
Authors: Sana M Al-Khatib; Anne S Hellkamp; Adrian F Hernandez; Gregg C Fonarow; Kevin L Thomas; Hussein R Al-Khalidi; Paul A Heidenreich; Stephen Hammill; Clyde Yancy; Eric D Peterson Journal: Circulation Date: 2012-01-27 Impact factor: 29.690
Authors: Giuseppe M C Rosano; Basil Lewis; Stefan Agewall; Sven Wassmann; Cristiana Vitale; Harald Schmidt; Heinz Drexel; Atul Patak; Christian Torp-Pedersen; Keld Per Kjeldsen; Juan Tamargo Journal: Eur Heart J Date: 2015-05-06 Impact factor: 29.983
Authors: Lars H Lund; Kiran K Khush; Wida S Cherikh; Samuel Goldfarb; Anna Y Kucheryavaya; Bronwyn J Levvey; Bruno Meiser; Joseph W Rossano; Daniel C Chambers; Roger D Yusen; Josef Stehlik Journal: J Heart Lung Transplant Date: 2017-07-20 Impact factor: 10.247
Authors: Emily P Zeitler; Anne S Hellkamp; Gregg C Fonarow; Stephen C Hammill; Lesley H Curtis; Adrian F Hernandez; Hussein R Al-Khalidi; Jeptha P Curtis; Paul A Heidenreich; Kevin J Anstrom; Eric D Peterson; Daniel B Mark; Bradley G Hammill; Gillian D Sanders; Sana M Al-Khatib Journal: JACC Heart Fail Date: 2014-11-05 Impact factor: 12.035
Authors: Camille G Frazier; Karen P Alexander; L Kristin Newby; Susan Anderson; Erik Iverson; Milton Packer; Jay Cohn; Sidney Goldstein; Pamela S Douglas Journal: J Am Coll Cardiol Date: 2007-03-21 Impact factor: 24.094
Authors: Pamela N Peterson; Stacie L Daugherty; Yongfei Wang; Humberto J Vidaillet; Paul A Heidenreich; Jeptha P Curtis; Frederick A Masoudi Journal: Circulation Date: 2009-02-16 Impact factor: 29.690
Authors: Mandeep R Mehra; Yoshifumi Naka; Nir Uriel; Daniel J Goldstein; Joseph C Cleveland; Paolo C Colombo; Mary N Walsh; Carmelo A Milano; Chetan B Patel; Ulrich P Jorde; Francis D Pagani; Keith D Aaronson; David A Dean; Kelly McCants; Akinobu Itoh; Gregory A Ewald; Douglas Horstmanshof; James W Long; Christopher Salerno Journal: N Engl J Med Date: 2016-11-16 Impact factor: 91.245
Authors: Laia Yáñez-Bisbe; Anna Garcia-Elias; Marta Tajes; Isaac Almendros; Antonio Rodríguez-Sinovas; Javier Inserte; Marisol Ruiz-Meana; Ramón Farré; Núria Farré; Begoña Benito Journal: Int J Mol Sci Date: 2021-12-24 Impact factor: 5.923